Reverse-engineering precision liver cancer chemoprevention

Ended Project Grant Awarded Last action

Award ID
R01CA233794
Recipient
Awarding agency
Obligated
$7,867,836

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date
Originally
Funding
  • $7,238,785.00 Federal
  • $629,051.00 Non-federal
Place of performance
Texas, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $199,439 $0
Amendment $199,439 $0
Amendment $613,866 $0
Amendment Reverse-engineering precision liver cancer chemoprevention - identification of clinically relevant cancer chemoprevention targets has been challenging. Our… $613,866 $0
Amendment $203,508 $0
Amendment $203,508 $0
Amendment Non-invasive monitoring of metabolic liver cancer risk - hepatocellular carcinoma (HCC) prognosis remains dismal due to frequent diagnosis at late,… $203,508 $0
Amendment Non-invasive monitoring of metabolic liver cancer risk - identification of clinically relevant cancer chemoprevention targets has been challenging. Our… $616,470 $0
Amendment $616,470 $0
Amendment $616,470 $0
Amendment Non-invasive monitoring of metabolic liver cancer risk - hepatocellular carcinoma (HCC) prognosis remains dismal due to frequent diagnosis at late,… $616,470 $0
Amendment $0 $0
Amendment $0 $0
Amendment $629,051 $0
Amendment Reverse-engineering precision liver cancer chemoprevention - identification of clinically relevant cancer chemoprevention targets has been challenging. Our… $629,051 $629,051
Amendment $623,745 $0
Amendment $0 $0
Original award $653,924 $0
Show all 21

Subawards

Subrecipient Amount Awarded
The General Hospital Corporation Provide clinical tissue and serum/plasma specimens from patients with non-alcoholic steatohepatitis for genetic profiling assay. $597,494
Institut National De La Sante Et De La Recherche Medicale Responsible for in vitro screening of bioinformatically prioritized compounds using the liver cancer risk signature-inducible cell system. $376,319

Quick answers

Who received award R01CA233794?

R01CA233794 was awarded to The University Of Texas Southwestern Medical Center by National Cancer Institute (National Institutes of Health) on September 23, 2019.

How much is award R01CA233794 worth?

$7,867,836 has been obligated on R01CA233794: $7,238,785 in federal funding and $629,051 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login